Premium
O4‐05‐01: Gwas of longitudinal amyloid PET identifies IL1RAP as a new potential Alzheimer's disease target
Author(s) -
Ramanan Vijay K.,
Risacher Shan L.,
Nho Kwangsik,
Kim Sungeun,
Shen Li,
Foroud Tatiana M.,
Aisen Paul S.,
Petersen Ronald C.,
Toga Arthur W.,
Green Robert C.,
Jagust William J.,
Weiner Michael W.,
Saykin Andrew J.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.07.369
Subject(s) - genome wide association study , apolipoprotein e , genotyping , medicine , genetic association , oncology , disease , genetics , biology , genotype , single nucleotide polymorphism , gene
statistically significant treatment differences for t-tau or p-tau in any population. Conclusions:Amyloid PET GCA SUVr decreases 10mg pooled dose suggests target engagement. There was no effect on neuronal injury biomarkers (p-tau and t-tau). Greater brain volume decreases in the MTM treatment groups was consistent with prior AD immunotherapy trials but the absence of treatment related differences in the small eAD study should be interpreted with caution.